Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors

Memantine extended release (ER) significantly outperformed placebo on co-primary endpoints of Clinician’s Interview-based Impression of Change Plus Caregiver Input (CIBIC-Plus) and baseline to endpoint changes on the Severe Impairment Battery (SIB) in a 24-week, randomized trial (NCT00322153) in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Grossberg, George T., Alva, Gustavo, Hendrix, Suzanne, Ellison, Noel, Kane, Mary C., Edwards, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110375/
https://www.ncbi.nlm.nih.gov/pubmed/29771687
http://dx.doi.org/10.1097/WAD.0000000000000261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110375/
https://www.ncbi.nlm.nih.gov/pubmed/29771687
http://dx.doi.org/10.1097/WAD.0000000000000261

Ejemplares similares